CVP alternating with fludarabine (CVP/F) chemotherapy prior to idiotype vaccination for follicular lymphoma (FL)

被引：0
|
作者：
Ai, W. Z.
Hsu, F. J.
Timmerman, J. M.
Czerwinski, D.
Taidi, B.
Levy, R.
Horning, S.
机构：
[1] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[2] Genzyme Corp, Framingham, MA 01701 USA
[3] Univ Calif Los Angeles, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8065
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Prolonged disease-free survival and overall survival with CVP alternating with fludarabine in advanced follicular lymphoma
    Ai, Weiyun Z.
    Kohrt, Holbrook E. K.
    Timmerman, John
    Hwang, Jimmy
    Hsu, Frank J.
    Czerwinski, Debra D.
    Taidi, Behnaz
    Levy, Ronald
    AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (06) : 515 - 518
  • [2] CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
    Marcus, R
    Imrie, K
    Belch, A
    Cunningham, D
    Flores, E
    Catalano, J
    Solal-Celigny, P
    Offner, F
    Walewski, J
    Raposo, J
    Jack, A
    Smith, P
    BLOOD, 2005, 105 (04) : 1417 - 1423
  • [3] Costs of toxicity during chemotherapy with CHOP, COP/CVP, and fludarabine
    Herold M.
    Hieke K.
    The European Journal of Health Economics, 2002, 3 (3) : 166 - 172
  • [4] G-CVP therapy using obinutuzumab for follicular lymphoma
    Yamada, Toshiki
    Tsurumi, Hisashi
    ANNALS OF ONCOLOGY, 2023, 34 : S1404 - S1404
  • [5] CVP plus rituximab compared to CVP alone in previously untreated patients with follicular lymphoma:: Impact of baseline prognostic factors
    Imrie, K
    Belch, A
    Pettengell, R
    Rueda, A
    McKendrick, J
    Solal-Céligny, P
    Offner, F
    Bence-Buckler, I
    Walewski, J
    Raposo, J
    Marcus, R
    ANNALS OF ONCOLOGY, 2005, 16 : 109 - 110
  • [6] ECONOMIC EVALUATION OF THE ADDITION OF RITUXIMAB TO CVP FOR ADVANCED FOLLICULAR LYMPHOMA IN ROMANIA
    Lupu, A. R.
    Radu, P. C.
    Ray, J. A.
    Kalfas, C. S.
    VALUE IN HEALTH, 2009, 12 (07) : A380 - A380
  • [7] Preliminary immune response (IR) results of a phase 2 study with idiotype (Id) immunotherapy after treatment with CVP and rituximab for follicular non-Hodgkin's lymphoma (FL).
    Leonard, J. P.
    Mason, K.
    Theriault, T.
    Milner, K.
    Sornasse, T.
    Ingolia, D. J. D.
    Mayo, M.
    Denney, D. W., Jr.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 429S - 429S
  • [8] Rituximab plus CVP chemotherapy vs. CVP alone as first-line treatment for follicular lymphoma:: Treatment effect according to baseline prognostic factors.
    Imrie, K
    Belch, A
    Pettengell, R
    Rueda, A
    McKendrick, J
    Solal-Céligny, P
    Offner, F
    Bence-Buckler, I
    Walewski, J
    Raposo, J
    Marcus, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 566S - 566S
  • [9] BiovaxID™ idiotype vaccination:: active immunotherapy for follicular lymphoma
    Flowers, Christopher R.
    EXPERT REVIEW OF VACCINES, 2007, 6 (03) : 307 - 317
  • [10] Idiotype vaccination in follicular lymphoma: Knocking on the doorway to cure
    Longo, Dan L.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (18): : 1263 - 1265
12345